Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525935 · ClinicalTrials.gov registry record · Phase 2
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
A Phase 2 study, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT06525935 is a Phase 2 study that has completed, run by Carmot Therapeutics. The registered enrollment target is 469 participants.
The verdict
NCT06525935, a Phase 2 study, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Interventions
- DRUG Placebo
- DRUG Enicepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06525935
The ClinicalTrials.gov registry entry for NCT06525935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carmot Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06525935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06525935 about?
NCT06525935 is a clinical study titled "A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity". This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
What is the current status of trial NCT06525935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2024-08-16. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT06525935?
The interventions under investigation include: Placebo (DRUG), Enicepatide (DRUG).
Who is sponsoring clinical trial NCT06525935?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.